JP5113958B2 - 薬剤多量体微粒子及びその製造方法 - Google Patents

薬剤多量体微粒子及びその製造方法 Download PDF

Info

Publication number
JP5113958B2
JP5113958B2 JP2012519401A JP2012519401A JP5113958B2 JP 5113958 B2 JP5113958 B2 JP 5113958B2 JP 2012519401 A JP2012519401 A JP 2012519401A JP 2012519401 A JP2012519401 A JP 2012519401A JP 5113958 B2 JP5113958 B2 JP 5113958B2
Authority
JP
Japan
Prior art keywords
general formula
drug
compound represented
group
fine particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012519401A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2011155501A1 (ja
Inventor
均 笠井
八郎 中西
耕一 馬場
英俊 及川
達也 村上
博 今堀
充 橋田
勇 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency, National Institute of Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Priority to JP2012519401A priority Critical patent/JP5113958B2/ja
Application granted granted Critical
Publication of JP5113958B2 publication Critical patent/JP5113958B2/ja
Publication of JPWO2011155501A1 publication Critical patent/JPWO2011155501A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012519401A 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法 Active JP5113958B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012519401A JP5113958B2 (ja) 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010133486 2010-06-11
JP2010133486 2010-06-11
PCT/JP2011/063084 WO2011155501A1 (ja) 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法
JP2012519401A JP5113958B2 (ja) 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012225014A Division JP2013040189A (ja) 2010-06-11 2012-10-10 薬剤多量体微粒子及びその製造方法

Publications (2)

Publication Number Publication Date
JP5113958B2 true JP5113958B2 (ja) 2013-01-09
JPWO2011155501A1 JPWO2011155501A1 (ja) 2013-08-01

Family

ID=45098106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012519401A Active JP5113958B2 (ja) 2010-06-11 2011-06-07 薬剤多量体微粒子及びその製造方法
JP2012225014A Pending JP2013040189A (ja) 2010-06-11 2012-10-10 薬剤多量体微粒子及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012225014A Pending JP2013040189A (ja) 2010-06-11 2012-10-10 薬剤多量体微粒子及びその製造方法

Country Status (5)

Country Link
US (1) US20130096097A1 (enExample)
EP (1) EP2586463B1 (enExample)
JP (2) JP5113958B2 (enExample)
CN (1) CN103068404B (enExample)
WO (1) WO2011155501A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
JP7626491B2 (ja) * 2021-03-12 2025-02-04 国立研究開発法人科学技術振興機構 Ｓｎ－３８誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法
CN120322442A (zh) * 2022-12-09 2025-07-15 国立研究开发法人科学技术振兴机构 化合物、纳米粒子、医药、及纳米粒子的制造方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0679168A (ja) * 1992-09-07 1994-03-22 Hitoshi Kasai 有機超微粒子の製法
WO2007075825A2 (en) * 2005-12-20 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
WO2009013466A1 (en) * 2007-07-20 2009-01-29 Fujifilm Manufacturing Europe B.V. Preparation of fine particles
WO2009075391A1 (en) * 2007-12-13 2009-06-18 Kyushu University, National University Corporation Drug-containing nanoparticles
CN101628919A (zh) * 2009-08-20 2010-01-20 浙江大学 喜树碱及其衍生物的自乳化药物前体及其应用
WO2010053101A1 (ja) * 2008-11-06 2010-05-14 国立大学法人東北大学 眼内移行性の高い点眼剤および蛍光イメージング剤ならびにそれらの製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
ES2262223T3 (es) 1997-02-14 2006-11-16 Bionumerik Pharmaceuticals, Inc. Derivados de camptotecina altamente lipofilos.
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
AU2003253890A1 (en) * 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
US20070041093A1 (en) 2005-08-22 2007-02-22 Stuart Bard Projector screen for use in a lighted room
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
CN101541332A (zh) 2006-09-15 2009-09-23 安佐制药股份有限公司 含多官能连接基的靶向聚合物前药

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0679168A (ja) * 1992-09-07 1994-03-22 Hitoshi Kasai 有機超微粒子の製法
WO2007075825A2 (en) * 2005-12-20 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
WO2009013466A1 (en) * 2007-07-20 2009-01-29 Fujifilm Manufacturing Europe B.V. Preparation of fine particles
WO2009075391A1 (en) * 2007-12-13 2009-06-18 Kyushu University, National University Corporation Drug-containing nanoparticles
WO2010053101A1 (ja) * 2008-11-06 2010-05-14 国立大学法人東北大学 眼内移行性の高い点眼剤および蛍光イメージング剤ならびにそれらの製造方法
CN101628919A (zh) * 2009-08-20 2010-01-20 浙江大学 喜树碱及其衍生物的自乳化药物前体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012030505; Ｊｏｕｒｎａｌ　ｏｆ　Ａｍｅｒｉｃａｎ　Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ Ｖｏｌ．１３２，　Ｎｏ．１２，ｐｐ．４２５９-４２６５，Ｓ１-１２, 20100310 *
JPN6012030509; Ａｎｇｅｗａｎｄｔｅ　Ｃｈｅｍｉｅ Ｖｏｌ．４４, 2005, ｐｐ．７１６-７２０，Ｓｕｐｐｏｒｔｉｎｇ　Ｉｎｆｏｒｍａｔｉｏｎｐｐ．１-２２ *
JPN7012002242; 高分子論文集 Ｖｏｌ．５９　，　Ｎｏ．１０，　ｐｐ．６３７-６４１, 2002 *

Also Published As

Publication number Publication date
EP2586463A1 (en) 2013-05-01
EP2586463A4 (en) 2014-03-19
EP2586463B1 (en) 2016-08-17
JPWO2011155501A1 (ja) 2013-08-01
WO2011155501A1 (ja) 2011-12-15
CN103068404A (zh) 2013-04-24
CN103068404B (zh) 2015-11-25
US20130096097A1 (en) 2013-04-18
JP2013040189A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
CA2543722C (en) Tocopherol-modified therapeutic drug compounds
JP5113958B2 (ja) 薬剤多量体微粒子及びその製造方法
WO2005118612A1 (en) Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
JP2019094260A (ja) 癌疾患治療用ナノ粒子化製剤
CN109021026A (zh) 顺铂药物前体、制备方法和应用
JP2021147340A (ja) 化合物、そのナノ粒子及び癌疾患の治療剤
CN114989182A (zh) 脂质化合物、包含其的组合物及应用
AU2016265922B2 (en) A pharmaceutical co-crystal and use thereof
WO2016045505A1 (zh) 一种喜树碱类磷脂化合物、其药物组合物及应用
AU2022314101B2 (en) Cyclohexane lipidoids for nucleic acid transfection and use thereof
CN118724740A (zh) 氨基脂质、脂质纳米颗粒及其应用
CN104193779A (zh) 一种pH敏感磷脂药用材料及其制备方法与应用
WO2013067881A1 (zh) 水溶性维生素e衍生物修饰的双亲性抗癌药物化合物和制剂、该化合物的制备方法及应用
ZA200604093B (en) Tocopherol-modified therapeutic drug compounds
AU2008269148B2 (en) Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin
CN118178664A (zh) 一种用于核酸递送的脂质材料及其用途
CN109044972A (zh) 共载紫杉醇的辣椒素前药聚合物胶束及其制备方法
CN107001617B (zh) Peg衍生物
CN102988293A (zh) 一种奥沙利铂叶酸靶向脂质体及其应用
CN116284006B (zh) 可电离脂质化合物、包含其的脂质载体及应用
CN113797195B (zh) 3-芳基香豆素类化合物的应用、抗癌增敏组合物及抗癌组合物
US20070148221A1 (en) Method of producing lipid complexed camptothecin-carboxylate
CN103772696B (zh) 一种羟基喜树碱的聚甘油脂肪酸酯衍生物
CN110845452A (zh) 一种卡巴他赛衍生物及其制备方法和应用
CN109602694A (zh) 喜树碱前药凝胶及其制备方法和用途

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120920

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121012

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151019

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5113958

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250